News and Press Releases
PADCEVTM (enfortumab vedotin) in Combination with Keytruda (pembrolizumab) Receives Positive CHMP Opinion for the Treatment of Patients with Resectable Muscle-Invasive Bladder Cancer who are Ineligible for Cisplatin-Based Chemotherapy
Positive opinion is based on data from the pivotal Phase 3 EV-303 trial showing a 60% reduction in the risk of disease recurrence, progression or death and a 50% reduction...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 22, 2026
NICE recommends WINREVAIR (Sotatercept) as a treatment option for adult patients in England and Wales with pulmonary arterial hypertension (PAH)
Sotatercept is indicated for use in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III,...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: May 14, 2026
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
NICE Recommends TEPKINLY▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy
Epcoritamab can now be accessed as an option to treat relapsed or refractory follicular lymphoma in adults after 2 or more lines of systemic treatment, only if epcoritamab is stopped...
Category: Drug Discovery, Other, Pharmaceutical
Posted: February 23, 2026
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
ACES-EMB is the first randomized-controlled trial to compare dd-cfDNA surveillance to routine biopsy in organ transplantation, highlighting the benefits of Prospera in organ rejection 28 January 2026 -- Texas, US...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2026
HeartBeat.bio and biotx.ai Sign License and Technology Access Agreement to Identify Novel Targets in Heart Failure
7 July 2025 -- Vienna, Austria and Berlin, Germany -- HeartBeat.bio AG and biotx.ai GmbH today announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. The collaboration combines biotx.ai’s causal...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 7, 2025
EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years
Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX compared to DES Significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with...
Category: Biotechnology, Clinical Trials, Other
Posted: May 21, 2025
Pharming receives positive recommendation from NICE for Joenja▼(leniolisib) as a treatment for APDS
Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands
Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC 25
Cleerly to Present Late-Breaking Findings and Participate in Key ACC 25 Sessions 27 March 2025 -- Illinois, US -- Cleerly, the leader in cardiovascular AI imaging, announces its participation in...
Category: Clinical Trials, Other, Pharmaceutical
Posted: March 27, 2025
SGLT2 HYPE – a guideline-relevant, clinical trial aiming to establish SGLT2 inhibitors as a new standard in hypertension therapy, ultimately addressing one of the leading causes of premature mortality in Germany and Europe
25 March 2025 -- Lübeck, Germany -- On January 1, 2025, the European research project SGLT2 HYPE (SGLT2 inhibition for cardiovascular reduction in HYPErtension) was officially launched, receiving €6.99 million...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
Clinigen collaborates with Servier to expand access to specialised oncology and haematology medicines in South Africa
17 March 2025 -- London, UK -- Clinigen, the global speciality pharmaceutical services group, today announced that Equity Pharmaceuticals, part of the Clinigen Group, has entered into a new collaboration...
Category: Drug Delivery, Other, Pharmaceutical
Posted: March 17, 2025
BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project
The research of BioMed X team EDC - Extrachromosomal DNA in Cancer - has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 6, 2025
Merck launches first-to-market, cyber-physical trust platform to tackle issues of product safety and counterfeiting
M-Trust™ is a secure cyber-physical trust platform that enables the creation of digital twins for enhanced product quality and authenticity assurances This cutting-edge new technology is being unveiled at CES...
Category: Biotechnology, Logistics, Other, Pharmaceutical
Posted: January 7, 2025
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
Santhera Receives Positive Recommendation from NICE for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
AGAMREE® has been recommended by NICE for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in England, Wales and Northern Ireland Santhera will be working...
Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
In the Overall Population, Achieved 28% Reduction in Primary Composite of All-Cause Mortality and Recurrent Cardiovascular Events, and 31% and 36% Reductions in All-Cause Mortality During the 33-36-Month Double-Blind Period...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 30, 2024
Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III
26 August, 2024 – New Jersey, US – Merck, known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved WINREVAIR™ (sotatercept), in...
Category: Pharmaceutical
Posted: August 28, 2024
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
